Debra Hughes, MS

Debra (Lumpe) Hughes has more than 3 decades of oncology medical writing and editing experience, including as a former editor of Oncology Times. She has a diverse background in medical journalism, education, and publishing. Her company, D.A. Hughes & Associates, provides medical communications services for academic institutions, communications and publishing companies, global pharmaceutical and biotechnology corporations, and professional medical associations and societies. Debra is an alumna of Columbia University Graduate School of Journalism, where she specialized in science writing, and the University of California, Riverside.

Most Recent Articles by Debra Hughes, MS

Q&A With Dr Chao: Oncotype DX Breast Recurrence Score® and Breast DCIS Score™

Q&A With Dr Chao: Oncotype DX Breast Recurrence Score® and Breast DCIS Score™

By

CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.

Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

By

Clinicians can use a geriatric assessment for an objective appraisal of the health status of older patients with multiple myeloma.

Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

By

Cancer Therapy Advisor asked Dr Andersen about whether it is possible to improve outcomes among patients with multiple myeloma by identifying those at risk of infection among the transplant-eligible.

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

By

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

Selecting A TKI for Chronic Myeloid Leukemia

Selecting A TKI for Chronic Myeloid Leukemia

By

TKI selection in the first line is based on risk score and TKI toxicity profile as well as the patient's age, ability to tolerate therapy, and comorbid conditions.

More Articles by Debra Hughes, MS

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters